Chugai Pharmaceutical Co., Ltd.

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 16/01/2026 GMT			5-day change	1st Jan Change
8,252.00 ^JPY	-3.98%		-2.01%	+0.11%

12-30	Chugai Completes Merger With Renalys Pharma	MT
12-29	Chugai Pharmaceutical Co., Ltd. completed the acquisition of Renalys Pharma.	CI

Chugai Pharmaceutical Co Ltd - enter into a license agreement for the development and commercialization of an oral formulation

Published on 10/20/2025 at 12:32 am BST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Chugai Pharmaceutical Co., Ltd.

12-30	Chugai Completes Merger With Renalys Pharma	MT
12-29	Chugai Pharmaceutical Co., Ltd. completed the acquisition of Renalys Pharma.	CI
12-18	Eli Lilly and Company Announces Oral GLP-1 Orforglipron	CI
11-18	Chugai Pharmaceutical to Absorb Renalys Pharma Following Full Acquisition	MT
11-12	Japan's Nikkei rises as SoftBank Group trims losses; Topix hits new high	RE
11-06	Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028	RE
24/10/25	Chugai Pharmaceutical to Acquire Renalys Pharma to Strengthen Kidney Disease Drug Portfolio	MT
24/10/25	Chugai Pharmaceutical's Net Income Rises 3.3% in Nine Months Period	MT
24/10/25	Renalys Pharma to be acquired by Chugai Pharmaceutical	RE
24/10/25	Chugai Pharmaceutical Co Ltd - Notice concerning making Renalys Pharma, Inc. a wholly-owned subsidiary	RE
23/10/25	Chugai Pharmaceutical Co., Ltd. agreed to acquire Renalys Pharma for ¥31 billion.	CI
20/10/25	Nikkei Soars as Investors Await New Premier, Trump Softens Tariff Stance	MT
20/10/25	Chugai, Rani Therapeutics Sign Licensing Deal to Advance Oral Biologic Formulation	MT
20/10/25	Chugai Pharmaceutical Co Ltd - enter into a license agreement for the development and commercialization of an oral formulation	RE
17/10/25	Top Midday Gainers	MT
17/10/25	Rani Therapeutics Enters Into Up to $1.09 Billion Collaboration, License Deal With Chugai Pharmaceutical -- Shares Rise Premarket	MT
17/10/25	Rani Therapeutics Shares Double After Deal With Chugai Pharma	DJ
01/10/25	Nikkei ends at three-week low on profit-taking as second half of fiscal year begins	RE
01/10/25	Nikkei falls on profit-taking at start of second half of fiscal year	RE
26/09/25	Japan's Topix posts record-high close despite US tariffs on pharma	RE
22/09/25	Japan's Nikkei ends higher as concerns over BOJ's ETF sales ease	RE
22/09/25	Japan's Nikkei rebounds as concerns over BOJ's ETF sales ease	RE
17/09/25	Chugai Pharmaceutical Co., Ltd. Announces Positive Topline Results from ACHIEVE-3	CI
27/08/25	Nikkei Gains Ahead Of Nvidia Earnings With Focus On China Risks	MT
27/08/25	Chugai Pharma Says Eli Lily's Orforglipron Phase 3 Trial Returns Positive Results	MT

Chart Chugai Pharmaceutical Co., Ltd.

Duration

Period

4519: Dynamic Chart

Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

Employees

5,026

Sector

Pharmaceuticals

Calendar

01-28 - Q4 2025 Earnings Release

More about the company